Evercore ISI lowered the firm’s price target on Ultragenyx (RARE) to $33 from $34 and keeps an Outperform rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Trump plans to fire FDA commissioner Marty Makary, WSJ reports
- Ultragenyx price target lowered to $26 from $27 at Wedbush
- Ultragenyx price target lowered to $43 from $52 at Guggenheim
- Ultragenyx Earnings Call: Growth, Gene Therapy and Risk
- Ultragenyx price target lowered to $43 from $44 at Barclays